Rockwell Medical Reports Q1 2026 Results and Updates Full-Year Guidance Focused on Profitability
Rockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a healthcare company specializing in the development, manufacturing, commercialization, and distribution of hemodialysis products for dialysis providers worldwide, has reported its financial and operational results for the three months ended March 31, 2026. Alongside its quarterly performance, the Company also provided an updated outlook for full-year 2026, emphasizing continued progress toward profitability, operational efficiency, and cash flow generation.
Strong Strategic Focus on Profitability and Efficiency
Dr. Mark Strobeck, President and Chief Executive Officer of Rockwell Medical, highlighted that the Company’s first-quarter performance reflects continued execution of its long-term strategy.
“Our financial and operational performance in the first quarter 2026 builds on the positive trajectory we have established across our key financial metrics, which we expect to continue throughout the remainder of the year,” said Dr. Strobeck. “By streamlining our operations, we are on track to generate meaningful cost savings that we believe will support sustained profitability. Our 2026 guidance is centered around strengthening revenue, expanding gross margin, and generating positive Adjusted EBITDA and cash flow.”
The Company’s strategic priorities remain centered on improving operational efficiency, optimizing pricing, and expanding its customer base within the global dialysis market.
First Quarter 2026 Financial Performance Overview
Rockwell Medical reported net sales of $17.3 million for the three months ended March 31, 2026, compared to $18.9 million in the same period of 2025, representing an 8% decline year-over-year. The decrease was primarily attributed to reduced purchase volumes from one key customer.
Despite the revenue decline, gross profit remained relatively stable at $2.9 million compared to $3.0 million in the prior-year period. This demonstrates resilience in the Company’s cost structure and product profitability.
Gross margin improved to 17% from 16% in the first quarter of 2025, reflecting better pricing discipline and operational efficiencies.
Operating Loss and Net Income Results
The Company reported an operating loss of $1.5 million for Q1 2026, slightly higher than the $1.4 million operating loss recorded in Q1 2025.
Net loss for the quarter was $1.6 million, compared to a net loss of $1.5 million in the prior-year period. The marginal increase reflects stable cost management despite lower sales volumes.
On a per-share basis, basic and diluted net loss remained unchanged at $0.04 per share for both periods.
Adjusted EPS was $(0.01) for both Q1 2026 and Q1 2025, indicating stable underlying performance when adjusted for non-GAAP items.
Adjusted EBITDA Shows Improvement
Adjusted EBITDA, a key non-GAAP performance metric used by the Company, improved to a loss of $0.3 million in Q1 2026 compared to a loss of $0.4 million in the same quarter of 2025.
This improvement reflects the Company’s continued focus on cost optimization and operational efficiency initiatives.
Rockwell Medical defines Adjusted EBITDA as net income adjusted for interest, taxes, depreciation, amortization, stock-based compensation, and other non-recurring or non-operational items.
Cash Position and Balance Sheet Strength
As of March 31, 2026, Rockwell Medical reported cash and cash equivalents, along with available-for-sale investments, totaling $23.9 million. This compares to $25.0 million as of December 31, 2025.
The decrease of approximately $1.1 million was primarily driven by seasonal working capital requirements and a $500,000 payment related to the acquisition of the hemodialysis concentrates business from Evoqua Water Technologies in 2023. The final payment associated with this acquisition was completed in April 2026.
The Company maintains a stable liquidity position, supporting ongoing operations and strategic initiatives.
Operational Highlights and Business Stability
Despite modest revenue pressure, Rockwell Medical demonstrated operational stability in its core business segments. The Company continues to supply critical hemodialysis products globally, serving dialysis clinics, hospitals, and other healthcare providers.
Demand for dialysis-related consumables remains structurally stable due to the growing global prevalence of end-stage kidney disease, which requires ongoing treatment through hemodialysis.
Rockwell Medical’s focus remains on ensuring consistent product supply, enhancing customer relationships, and improving manufacturing efficiency.
Updated Full-Year 2026 Guidance
The Company has updated its full-year 2026 financial guidance, reflecting expectations for continued operational improvement and margin expansion.
Rockwell Medical expects net sales for the full year 2026 to range between $70.0 million and $75.0 million. This projection includes expected revenue contributions from new customer onboarding and pricing adjustments.
Gross margin is projected to improve significantly, ranging between 18% and 22%, supported by cost reductions and pricing optimization strategies.
Adjusted EBITDA is expected to range from $1.0 million to $2.0 million, marking a return to positive profitability on an adjusted basis.
The Company also anticipates generating positive operating cash flow for the full year 2026, underscoring its improving financial sustainability.
Revenue Growth and Cost Savings Initiatives
Rockwell Medical outlined two primary drivers supporting its updated outlook:
First, the Company is implementing targeted pricing adjustments designed to better align product pricing with current market conditions. These changes are expected to generate more than $1 million in annualized incremental revenue.
Second, the Company is executing operational streamlining initiatives, including improvements to its distribution network and internal cost structure. These actions are expected to deliver more than $2 million in annualized cost savings.
Together, these initiatives are intended to strengthen margins and support long-term profitability.
Webcast and Investor Engagement
The Company hosted a conference call and webcast on May 7, 2026, at 8:00 a.m. ET to discuss its financial results and business outlook.
The session featured presentations from Dr. Mark Strobeck, President and CEO, and Jesse Neri, Senior Vice President and Chief Financial Officer. The discussion included a detailed review of Q1 2026 performance, strategic initiatives, and forward-looking guidance, followed by a question-and-answer session with investors.
A replay of the webcast is available on the Company’s investor relations website.
Understanding Non-GAAP Financial Measures
Rockwell Medical utilizes non-GAAP financial measures, including Adjusted EBITDA and Adjusted EPS, to supplement its GAAP reporting.
Adjusted EBITDA excludes non-operational items such as depreciation, amortization, stock-based compensation, and other non-recurring expenses. Adjusted EPS is derived from Adjusted EBITDA and divided by weighted average shares outstanding.
The Company believes these measures provide additional insight into underlying operational performance and facilitate period-over-period comparisons. However, they should not be considered in isolation or as substitutes for GAAP results.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company focused on developing, manufacturing, and distributing hemodialysis products used in the treatment of end-stage kidney disease. Its products are used in dialysis centers, hospitals, and other healthcare facilities worldwide.
The Company is committed to delivering high-quality dialysis solutions supported by strong customer service and operational reliability. Hemodialysis remains a critical, life-sustaining treatment for patients with kidney failure.
Rockwell Medical continues to focus on innovation, operational excellence, and long-term growth strategies to enhance patient care and healthcare system value.
The Company has been certified as a Great Place to Work® for four consecutive years (2023–2026) and was named among Fortune’s Best Workplaces in Manufacturing & Production™ in 2024 and 2025.
Rockwell Medical’s mission remains centered on delivering reliable, life-sustaining dialysis solutions to patients worldwide.
Source link:https://www.businesswire.com/
